Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer

The ability of dendritic cells to provide all the signals required for T-cell activation makes them an ideal cancer vaccine platform. With the use of established DC2.4 cell line, originated from C57BL/6 mice and developed by superinfecting GM-CSF transduced bone marrow cells with myc and raf oncogen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2012-11, Vol.14 (3), p.252-260
Hauptverfasser: Zhang, Pei, Wang, Jinyan, Wang, Danan, Wang, Huan, Shan, Fengping, Chen, Liudan, Hou, Ying, Wang, Enhua, Lu, Chang-long
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 260
container_issue 3
container_start_page 252
container_title International immunopharmacology
container_volume 14
creator Zhang, Pei
Wang, Jinyan
Wang, Danan
Wang, Huan
Shan, Fengping
Chen, Liudan
Hou, Ying
Wang, Enhua
Lu, Chang-long
description The ability of dendritic cells to provide all the signals required for T-cell activation makes them an ideal cancer vaccine platform. With the use of established DC2.4 cell line, originated from C57BL/6 mice and developed by superinfecting GM-CSF transduced bone marrow cells with myc and raf oncogenes, we investigated whether the DC 2.4 cell line transfected with Ag85A gene could enhance immunity against bladder cancer. Both phenotypic and functional analyses of Ag85A‐DCs were done with use of FCM and T cell proliferation test. The cytotoxicity of Ag85A-DCs loaded with tumor cell lysate was verified by LDH. Finally, the production of interferon gamma was assayed by both ELISA and FCM. The immunotherapeutic effect of DC vaccine on murine bladder cancer was assessed pharmacologically and pathologically. Our results showed that Ag85A gene transfected DCs expressed high levels of key surface markers such as CD80, CD86 and MHC-II. The CTL primed with MB49 lysate-pulsed Ag85A-DCs elicits higher activity against MB49 tumor cells and upregulated level of IFN-γ production. Furthermore, the significant inhibitive effect on tumor growth in mice was found in the group of Ag85A-DC vaccine. The infiltration of CD4+ or CD8+ T cell within established tumor treated by Ag85A-DC vaccine significantly increased as compared with control groups. It is therefore concluded that DCs engineered by Ag85A gene exerts enhanced anti-tumor immunity against bladder cancer and this study might provide a meaningful mode of action with the use of Ag85A engineered DC vaccination in anti-cancer immunotherapy. ► Ag85A gene transfection could markedly induce phenotypic and functional maturation of DC2.4 cells. ► Ag85A-DC vaccine could markedly enhance infiltration of CD4+ and CD8+ T cells in tumor tissues. ► Ag85A-DC vaccine could markedly increase production of IFN-γ, triggering a chain of cellular immune response. ► Ag85A-DC vaccine could markedly elicit mouse with anti-tumor effect against bladder cancer.
doi_str_mv 10.1016/j.intimp.2012.07.014
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1081872218</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576912002238</els_id><sourcerecordid>1081872218</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-19b4ecc8a2ada0582bd58436ae67d818aa0b027f888d584091bd7a3970a96e673</originalsourceid><addsrcrecordid>eNp9kEtr3DAQgEVoyKv5B6XoUsjFjqS1LflSWJI0DQRySc9iLI03s_ixlezA_vvI7La99TTD6JuHPsa-SJFLIavbbU7DRP0uV0KqXOhcyOKEXUijTSa1KD-lvKx0VuqqPmeXMW6FSPVCnrFzpYwpSikvGNzj4ANN5LjDruPv4BwNyPvRU0voebPn640p13yDqYzDGwwOI4e0O5vmfgyc-n4eaNpz2AANceJNB95j4G5Bw2d22kIX8foYr9ivHw-vdz-z55fHp7v1c-ZWtZoyWTcFOmdAgQdRGtX40hSrCrDS3kgDIBqhdGuMWR5ELRuvYVVrAXWVmNUVuznM3YXx94xxsj3F5U8w4DhHK0WaopWSJqHFAXVhjDFga3eBegj7BNlFrt3ag1y7yLVC2yQ3tX09bpibHv3fpj82E_DtCEB00LUhCaD4j6vS4bJauO8HDpOPd8JgoyNMsjwFdJP1I_3_kg_-VJmi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1081872218</pqid></control><display><type>article</type><title>Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Zhang, Pei ; Wang, Jinyan ; Wang, Danan ; Wang, Huan ; Shan, Fengping ; Chen, Liudan ; Hou, Ying ; Wang, Enhua ; Lu, Chang-long</creator><creatorcontrib>Zhang, Pei ; Wang, Jinyan ; Wang, Danan ; Wang, Huan ; Shan, Fengping ; Chen, Liudan ; Hou, Ying ; Wang, Enhua ; Lu, Chang-long</creatorcontrib><description>The ability of dendritic cells to provide all the signals required for T-cell activation makes them an ideal cancer vaccine platform. With the use of established DC2.4 cell line, originated from C57BL/6 mice and developed by superinfecting GM-CSF transduced bone marrow cells with myc and raf oncogenes, we investigated whether the DC 2.4 cell line transfected with Ag85A gene could enhance immunity against bladder cancer. Both phenotypic and functional analyses of Ag85A‐DCs were done with use of FCM and T cell proliferation test. The cytotoxicity of Ag85A-DCs loaded with tumor cell lysate was verified by LDH. Finally, the production of interferon gamma was assayed by both ELISA and FCM. The immunotherapeutic effect of DC vaccine on murine bladder cancer was assessed pharmacologically and pathologically. Our results showed that Ag85A gene transfected DCs expressed high levels of key surface markers such as CD80, CD86 and MHC-II. The CTL primed with MB49 lysate-pulsed Ag85A-DCs elicits higher activity against MB49 tumor cells and upregulated level of IFN-γ production. Furthermore, the significant inhibitive effect on tumor growth in mice was found in the group of Ag85A-DC vaccine. The infiltration of CD4+ or CD8+ T cell within established tumor treated by Ag85A-DC vaccine significantly increased as compared with control groups. It is therefore concluded that DCs engineered by Ag85A gene exerts enhanced anti-tumor immunity against bladder cancer and this study might provide a meaningful mode of action with the use of Ag85A engineered DC vaccination in anti-cancer immunotherapy. ► Ag85A gene transfection could markedly induce phenotypic and functional maturation of DC2.4 cells. ► Ag85A-DC vaccine could markedly enhance infiltration of CD4+ and CD8+ T cells in tumor tissues. ► Ag85A-DC vaccine could markedly increase production of IFN-γ, triggering a chain of cellular immune response. ► Ag85A-DC vaccine could markedly elicit mouse with anti-tumor effect against bladder cancer.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2012.07.014</identifier><identifier>PMID: 22884511</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Acyltransferases - genetics ; Ag85A ; Animals ; Antigens, Bacterial - genetics ; Biological and medical sciences ; Bladder cancer ; Cancer Vaccines ; Cell Line ; Cell Line, Tumor ; Cell Proliferation ; Dendritic cells ; Dendritic Cells - immunology ; Immunotherapy ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Nephrology. Urinary tract diseases ; Pharmacology. Drug treatments ; T-Lymphocytes - immunology ; Tumors of the urinary system ; Urinary Bladder Neoplasms - immunology ; Urinary Bladder Neoplasms - therapy ; Urinary system involvement in other diseases. Miscellaneous ; Urinary tract. Prostate gland ; Vaccine</subject><ispartof>International immunopharmacology, 2012-11, Vol.14 (3), p.252-260</ispartof><rights>2012 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-19b4ecc8a2ada0582bd58436ae67d818aa0b027f888d584091bd7a3970a96e673</citedby><cites>FETCH-LOGICAL-c392t-19b4ecc8a2ada0582bd58436ae67d818aa0b027f888d584091bd7a3970a96e673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2012.07.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26584161$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22884511$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Pei</creatorcontrib><creatorcontrib>Wang, Jinyan</creatorcontrib><creatorcontrib>Wang, Danan</creatorcontrib><creatorcontrib>Wang, Huan</creatorcontrib><creatorcontrib>Shan, Fengping</creatorcontrib><creatorcontrib>Chen, Liudan</creatorcontrib><creatorcontrib>Hou, Ying</creatorcontrib><creatorcontrib>Wang, Enhua</creatorcontrib><creatorcontrib>Lu, Chang-long</creatorcontrib><title>Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>The ability of dendritic cells to provide all the signals required for T-cell activation makes them an ideal cancer vaccine platform. With the use of established DC2.4 cell line, originated from C57BL/6 mice and developed by superinfecting GM-CSF transduced bone marrow cells with myc and raf oncogenes, we investigated whether the DC 2.4 cell line transfected with Ag85A gene could enhance immunity against bladder cancer. Both phenotypic and functional analyses of Ag85A‐DCs were done with use of FCM and T cell proliferation test. The cytotoxicity of Ag85A-DCs loaded with tumor cell lysate was verified by LDH. Finally, the production of interferon gamma was assayed by both ELISA and FCM. The immunotherapeutic effect of DC vaccine on murine bladder cancer was assessed pharmacologically and pathologically. Our results showed that Ag85A gene transfected DCs expressed high levels of key surface markers such as CD80, CD86 and MHC-II. The CTL primed with MB49 lysate-pulsed Ag85A-DCs elicits higher activity against MB49 tumor cells and upregulated level of IFN-γ production. Furthermore, the significant inhibitive effect on tumor growth in mice was found in the group of Ag85A-DC vaccine. The infiltration of CD4+ or CD8+ T cell within established tumor treated by Ag85A-DC vaccine significantly increased as compared with control groups. It is therefore concluded that DCs engineered by Ag85A gene exerts enhanced anti-tumor immunity against bladder cancer and this study might provide a meaningful mode of action with the use of Ag85A engineered DC vaccination in anti-cancer immunotherapy. ► Ag85A gene transfection could markedly induce phenotypic and functional maturation of DC2.4 cells. ► Ag85A-DC vaccine could markedly enhance infiltration of CD4+ and CD8+ T cells in tumor tissues. ► Ag85A-DC vaccine could markedly increase production of IFN-γ, triggering a chain of cellular immune response. ► Ag85A-DC vaccine could markedly elicit mouse with anti-tumor effect against bladder cancer.</description><subject>Acyltransferases - genetics</subject><subject>Ag85A</subject><subject>Animals</subject><subject>Antigens, Bacterial - genetics</subject><subject>Biological and medical sciences</subject><subject>Bladder cancer</subject><subject>Cancer Vaccines</subject><subject>Cell Line</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Dendritic cells</subject><subject>Dendritic Cells - immunology</subject><subject>Immunotherapy</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>T-Lymphocytes - immunology</subject><subject>Tumors of the urinary system</subject><subject>Urinary Bladder Neoplasms - immunology</subject><subject>Urinary Bladder Neoplasms - therapy</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><subject>Urinary tract. Prostate gland</subject><subject>Vaccine</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtr3DAQgEVoyKv5B6XoUsjFjqS1LflSWJI0DQRySc9iLI03s_ixlezA_vvI7La99TTD6JuHPsa-SJFLIavbbU7DRP0uV0KqXOhcyOKEXUijTSa1KD-lvKx0VuqqPmeXMW6FSPVCnrFzpYwpSikvGNzj4ANN5LjDruPv4BwNyPvRU0voebPn640p13yDqYzDGwwOI4e0O5vmfgyc-n4eaNpz2AANceJNB95j4G5Bw2d22kIX8foYr9ivHw-vdz-z55fHp7v1c-ZWtZoyWTcFOmdAgQdRGtX40hSrCrDS3kgDIBqhdGuMWR5ELRuvYVVrAXWVmNUVuznM3YXx94xxsj3F5U8w4DhHK0WaopWSJqHFAXVhjDFga3eBegj7BNlFrt3ag1y7yLVC2yQ3tX09bpibHv3fpj82E_DtCEB00LUhCaD4j6vS4bJauO8HDpOPd8JgoyNMsjwFdJP1I_3_kg_-VJmi</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>Zhang, Pei</creator><creator>Wang, Jinyan</creator><creator>Wang, Danan</creator><creator>Wang, Huan</creator><creator>Shan, Fengping</creator><creator>Chen, Liudan</creator><creator>Hou, Ying</creator><creator>Wang, Enhua</creator><creator>Lu, Chang-long</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121101</creationdate><title>Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer</title><author>Zhang, Pei ; Wang, Jinyan ; Wang, Danan ; Wang, Huan ; Shan, Fengping ; Chen, Liudan ; Hou, Ying ; Wang, Enhua ; Lu, Chang-long</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-19b4ecc8a2ada0582bd58436ae67d818aa0b027f888d584091bd7a3970a96e673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Acyltransferases - genetics</topic><topic>Ag85A</topic><topic>Animals</topic><topic>Antigens, Bacterial - genetics</topic><topic>Biological and medical sciences</topic><topic>Bladder cancer</topic><topic>Cancer Vaccines</topic><topic>Cell Line</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Dendritic cells</topic><topic>Dendritic Cells - immunology</topic><topic>Immunotherapy</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>T-Lymphocytes - immunology</topic><topic>Tumors of the urinary system</topic><topic>Urinary Bladder Neoplasms - immunology</topic><topic>Urinary Bladder Neoplasms - therapy</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><topic>Urinary tract. Prostate gland</topic><topic>Vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Pei</creatorcontrib><creatorcontrib>Wang, Jinyan</creatorcontrib><creatorcontrib>Wang, Danan</creatorcontrib><creatorcontrib>Wang, Huan</creatorcontrib><creatorcontrib>Shan, Fengping</creatorcontrib><creatorcontrib>Chen, Liudan</creatorcontrib><creatorcontrib>Hou, Ying</creatorcontrib><creatorcontrib>Wang, Enhua</creatorcontrib><creatorcontrib>Lu, Chang-long</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Pei</au><au>Wang, Jinyan</au><au>Wang, Danan</au><au>Wang, Huan</au><au>Shan, Fengping</au><au>Chen, Liudan</au><au>Hou, Ying</au><au>Wang, Enhua</au><au>Lu, Chang-long</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>14</volume><issue>3</issue><spage>252</spage><epage>260</epage><pages>252-260</pages><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>The ability of dendritic cells to provide all the signals required for T-cell activation makes them an ideal cancer vaccine platform. With the use of established DC2.4 cell line, originated from C57BL/6 mice and developed by superinfecting GM-CSF transduced bone marrow cells with myc and raf oncogenes, we investigated whether the DC 2.4 cell line transfected with Ag85A gene could enhance immunity against bladder cancer. Both phenotypic and functional analyses of Ag85A‐DCs were done with use of FCM and T cell proliferation test. The cytotoxicity of Ag85A-DCs loaded with tumor cell lysate was verified by LDH. Finally, the production of interferon gamma was assayed by both ELISA and FCM. The immunotherapeutic effect of DC vaccine on murine bladder cancer was assessed pharmacologically and pathologically. Our results showed that Ag85A gene transfected DCs expressed high levels of key surface markers such as CD80, CD86 and MHC-II. The CTL primed with MB49 lysate-pulsed Ag85A-DCs elicits higher activity against MB49 tumor cells and upregulated level of IFN-γ production. Furthermore, the significant inhibitive effect on tumor growth in mice was found in the group of Ag85A-DC vaccine. The infiltration of CD4+ or CD8+ T cell within established tumor treated by Ag85A-DC vaccine significantly increased as compared with control groups. It is therefore concluded that DCs engineered by Ag85A gene exerts enhanced anti-tumor immunity against bladder cancer and this study might provide a meaningful mode of action with the use of Ag85A engineered DC vaccination in anti-cancer immunotherapy. ► Ag85A gene transfection could markedly induce phenotypic and functional maturation of DC2.4 cells. ► Ag85A-DC vaccine could markedly enhance infiltration of CD4+ and CD8+ T cells in tumor tissues. ► Ag85A-DC vaccine could markedly increase production of IFN-γ, triggering a chain of cellular immune response. ► Ag85A-DC vaccine could markedly elicit mouse with anti-tumor effect against bladder cancer.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>22884511</pmid><doi>10.1016/j.intimp.2012.07.014</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1567-5769
ispartof International immunopharmacology, 2012-11, Vol.14 (3), p.252-260
issn 1567-5769
1878-1705
language eng
recordid cdi_proquest_miscellaneous_1081872218
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Acyltransferases - genetics
Ag85A
Animals
Antigens, Bacterial - genetics
Biological and medical sciences
Bladder cancer
Cancer Vaccines
Cell Line
Cell Line, Tumor
Cell Proliferation
Dendritic cells
Dendritic Cells - immunology
Immunotherapy
Medical sciences
Mice
Mice, Inbred C57BL
Nephrology. Urinary tract diseases
Pharmacology. Drug treatments
T-Lymphocytes - immunology
Tumors of the urinary system
Urinary Bladder Neoplasms - immunology
Urinary Bladder Neoplasms - therapy
Urinary system involvement in other diseases. Miscellaneous
Urinary tract. Prostate gland
Vaccine
title Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T12%3A22%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dendritic%20cell%20vaccine%20modified%20by%20Ag85A%20gene%20enhances%20anti-tumor%20immunity%20against%20bladder%20cancer&rft.jtitle=International%20immunopharmacology&rft.au=Zhang,%20Pei&rft.date=2012-11-01&rft.volume=14&rft.issue=3&rft.spage=252&rft.epage=260&rft.pages=252-260&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2012.07.014&rft_dat=%3Cproquest_cross%3E1081872218%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1081872218&rft_id=info:pmid/22884511&rft_els_id=S1567576912002238&rfr_iscdi=true